Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
funds
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.00 | 6.00 | 0.07% |
| CAC 40 | 7,665.91 | 25.64 | -0.33% |
| DAX 40 | 23,909.61 | 123.61 | -0.51% |
| Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
| FTSE 100 | 8,760.96 | 37.95 | -0.43% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,369.73 | 96.27 | 0.47% |
| Nikkei 225 | 40,019.94 | 467.45 | -1.15% |
| NZX 50 Index | 12,646.56 | 43.74 | 0.35% |
| S&P 500 | 6,204.95 | 31.88 | 0.52% |
| S&P/ASX 200 | 8,548.50 | 6.20 | 0.07% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |